We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court yesterday upheld a lower court ruling that found generic firm Impax did not infringe on a patent covering GlaxoSmithKline’s (GSK’s) top selling antidepressant Wellbutrin SR (bupropion HCl) extended-release tablets.
Apotex has dropped an antitrust lawsuit against eye care drugmaker Allergan that alleges the firm improperly obtained a patent to prevent generic competition on its anti-inflammatory eye drug Acular.
Purdue Pharma has filed its notice of appeal with the trial court that recently ruled that some of its patents for the powerful pain drug OxyContin (oxycodone) are invalid.
Eon Labs has started shipping the first generic version of GlaxoSmithKline’s (GSK’s) profitable antidepressant Wellbutrin SR (bupropion HCl extended release) in 100-mg strength tablets.
The FDA’s decision to award Alpharma subsidiary Purepac 180-day marketing exclusivity for a generic version of Pfizer’s epilepsy drug Neurontin (gabapentin) has been upheld by a federal appeals court.
The FDA’s draft guidance on pharmacogenomics that calls for voluntary genomic data submissions (VGDSs) needs more detail on how drugmakers’ proprietary interests would be protected, Eli Lilly told the agency in comments recently.
A federal appeals court has upheld the FDA’s decision to award Alpharma subsidiary Purepac the 180-day marketing exclusivity for a generic version of Pfizer’s Neurontin, which the FDA has approved for treating epilepsy.